Pulmonx director Florin Daniel P buys $71,362 in common stock

Published 06/06/2025, 01:44
Pulmonx director Florin Daniel P buys $71,362 in common stock

Florin Daniel P, a director at Pulmonx Corp (NASDAQ:LUNG), recently purchased 23,321 shares of the company’s common stock, according to a filing with the Securities and Exchange Commission. The purchase comes as the stock trades near its 52-week low of $2.83, having declined over 53% in the past six months. The shares were acquired on June 5, 2025, at a weighted average price of $3.06 per share, totaling approximately $71,362. The purchase occurred at prices ranging from $3.01 to $3.09 per share. According to InvestingPro analysis, the company maintains strong liquidity with a current ratio of 4.97 and holds more cash than debt on its balance sheet. Following this transaction, Daniel now holds 117,231 shares directly. InvestingPro analysis suggests the stock is currently undervalued, with 8 additional key insights available to subscribers through the comprehensive Pro Research Report.

In other recent news, Pulmonx Corp reported its first-quarter 2025 earnings, revealing a smaller-than-expected loss per share of $0.36, surpassing the forecasted loss of $0.39. However, the company slightly missed revenue projections, posting $22.5 million against an expected $22.03 million. Despite this, Pulmonx reaffirmed its full-year revenue guidance between $96 million and $98 million, anticipating growth acceleration in the U.S. later in the year. Stifel analysts maintained their Buy rating for Pulmonx, with a price target of $16, citing expected sales growth in the latter half of 2025 due to strategic commercial initiatives. Meanwhile, Canaccord Genuity adjusted their price target for Pulmonx to $15 from $16 but upheld a Buy rating, expressing confidence in the company’s potential for long-term growth. Pulmonx’s management has indicated that U.S. sales growth will be bolstered by initiatives such as the rollout of LungTraX Connect/Detect and the addition of new Zephyr Valve therapy awareness specialists. The company also continues to expand internationally, with notable revenue growth in China and other markets.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.